![]() |
Name |
2-(2-Vinyloxy-ethoxy)-cyclohexanol
|
Molecular Formula | C10H18O3 | |
IUPAC Name* |
2-(2-ethenoxyethoxy)cyclohexan-1-ol
|
|
SMILES |
C=COCCOC1CCCCC1O
|
|
InChI |
InChI=1S/C10H18O3/c1-2-12-7-8-13-10-6-4-3-5-9(10)11/h2,9-11H,1,3-8H2
|
|
InChIKey |
UNRYVNFCBOHOHN-UHFFFAOYSA-N
|
|
Synonyms |
2-(2-Vinyloxy-ethoxy)-cyclohexanol
|
|
CAS | NA | |
PubChem CID | 550853 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 186.25 | ALogp: | 1.3 |
HBD: | 1 | HBA: | 3 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 38.7 | Aromatic Rings: | 1 |
Heavy Atoms: | 13 | QED Weighted: | 0.527 |
Caco-2 Permeability: | -4.426 | MDCK Permeability: | 0.00003920 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.013 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.017 |
30% Bioavailability (F30%): | 0.03 |
Blood-Brain-Barrier Penetration (BBB): | 0.247 | Plasma Protein Binding (PPB): | 15.32% |
Volume Distribution (VD): | 1.057 | Fu: | 73.84% |
CYP1A2-inhibitor: | 0.036 | CYP1A2-substrate: | 0.377 |
CYP2C19-inhibitor: | 0.055 | CYP2C19-substrate: | 0.729 |
CYP2C9-inhibitor: | 0.017 | CYP2C9-substrate: | 0.265 |
CYP2D6-inhibitor: | 0.006 | CYP2D6-substrate: | 0.392 |
CYP3A4-inhibitor: | 0.044 | CYP3A4-substrate: | 0.254 |
Clearance (CL): | 8.518 | Half-life (T1/2): | 0.66 |
hERG Blockers: | 0.026 | Human Hepatotoxicity (H-HT): | 0.302 |
Drug-inuced Liver Injury (DILI): | 0.033 | AMES Toxicity: | 0.251 |
Rat Oral Acute Toxicity: | 0.087 | Maximum Recommended Daily Dose: | 0.138 |
Skin Sensitization: | 0.601 | Carcinogencity: | 0.948 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.522 |
Respiratory Toxicity: | 0.218 |